Panel discussion: Targeted immunomodulation in airway epithelium to treat pneumonia J-C Sirard (Lille, France), Prof. Scott Evans (Houston, Texas), M. Baldry (Lille, France), N. Heuzé-Vourc’h (Tours, France)
Thursday, 12 January 2023 | |
Introduction T. Welte (Hannover, Germany), A. Liapikou (Athens, Greece)
| |
Interactive discussion guided by MCQs T. Welte (Hannover, Germany), R. Botgros (Amsterdam, Netherlands), C. Prat Aymerich (Utrecht, Netherlands), C. van Werkhoven (Utrecht, Netherlands)
| |
Adaptative trials in respiratory tract infections C. van Werkhoven (Utrecht, Netherlands)
| |
Definition criteria of pneumonia from the perspective of regulatory agencies R. Botgros (Amsterdam, Netherlands)
| |
Advances in microbiological diagnosis of respiratory tract infections C. Prat Aymerich (Utrecht, Netherlands)
| |
Strengths and limitations of clinical trials in pneumonia T. Welte (Hannover, Germany)
| |
Management of complicated pneumonia in children M. Proesmans (Leuven, Belgium)
| |
Late Breaking Abstract - Are undernutrition and obesity associated with poor outcomes after hospitalization with community-acquired pneumonia – a prospective cohort study. M. Hegelund (Hillerød, Denmark), C. Ryrsø (Hillerød, Denmark), C. Ritz (Copenhagen, Denmark), A. Dungu (Hillerød, Denmark), R. Krogh-Madsen (Hvidovre, Denmark), B. Lindegaard (Hillerød, Denmark), D. Faurholt-Jepsen (Copenhagen, Denmark)
| |
The diagnostic and prognostic role of plasminogen activator inhibitor-1 (PAI-1) in hospitalized patients with pneumonias of different etiologies K. Bielosludtseva (Dniepropetrovsk, Ukraine)
| |
Neutrophils in elderly hospitalised community acquired pneumonia patients are immature and migrate inaccurately A. Faniyi (Birmingham, United Kingdom), F. Grudzinska (Birmingham, United Kingdom), O. Thein (Birmingham, United Kingdom), K. Belchamber (Birmingham, United Kingdom), J. Patel (Birmingham, United Kingdom), D. Parekh (Birmingham, United Kingdom), A. Scott (Birmingham, United Kingdom), E. Sapey (Birmingham, United Kingdom), D. Thickett (Birmingham, United Kingdom), S. Thein (Birmingham (West Midlands), United Kingdom)
| |
Development of AI models to predict mortality and long-term hospitalization in pneumonia T. Furukawa (Nagoya (Aichi), Japan), S. Oyama (Nagoya (Aichi), Japan), K. Sato (Nagoya (Aichi), Japan), S. Misawa (Tokyo, Japan), R. Kano (Tokyo, Japan), H. Yarimizu (Tokyo, Japan), Y. Shiratori (Nagoya (Aichi), Japan)
| |
Impact of severe lymphopenia on outcome of patients with pneumonia and positive pneumococcal urinary antigen L. Ruiz Iturriaga (Barakaldo (Vizcaya), Spain), L. Serrano Fernández (Barakaldo (Vizcaya), Spain), S. Pérez-Fernández (Barakaldo (Vizcaya), Spain), S. Castro Quintas (Barakaldo (Vizcaya), Spain), A. Urrutia Gajate (Barakaldo (Vizcaya), Spain), B. González Quero (Barakaldo (Vizcaya), Spain), A. Rezola Carasusan (Barakaldo (Vizcaya), Spain), A. Artaraz Ereño (Galdakao (Vizcaya), Spain), A. Gómez Bonilla (Barakaldo (Vizcaya), Spain), P. España Yandiola (Galdakao (Vizcaya), Spain), R. Zalacain Jorge (Barakaldo (Vizcaya), Spain)
| |
Patients with COVID-19 versus non-COVID-19 community-acquired pneumonia A. Liapikou (Athens, Greece), H. Milionis (Ioannina, Greece), A. Liontos (Ioannina, Greece), V. Tsimihodimos (Ioannina, Greece), A. Konstantinidis (Ioannina, Greece), K. Exarchos (Ioannina, Greece), K. Gartzonika (Ioannina, Greece), C. Kittas (Ioannina, Greece), G. Baxevanos (Ioannina, Greece), T. Tzimas (Ioannina, Greece), E. Chrysostomou (Ioannina, Greece), N. Zotos (Ioannina, Greece), L. Papageorgiou (Ioannina, Greece), C. Terrovitou (Kavala, Greece), D. Daniilidis (Kavala, Greece), C. Triantafyllidis (Kavala, Greece), T. Argiriadou (Kavala, Greece), A. Chli (Kavala, Greece), E. Tsouchnika (Kavala, Greece), V. Kossyvaki (Athens, Greece), J. Skiadas (Athens, Greece), D. Menegas (Athens, Greece), C. Méndez (Madrid, Spain), C. Schwarz (Vienna, Austria), E. Begier (Collegeville, United States), B. D. Gessner (Collegeville, United States), M. Toumbis (Athens, Greece), S. Egnatia Group (Athens, Greece), A. Konstantinidis (Ioannina, Greece)
| |
Machine learning for mortality prediction in community-acquired pneumonia emergency admissions D. Lozano-Rojas (Leicester, United Kingdom), A. Mcewan (Leicester, United Kingdom), G. Woltmann (Leicester, United Kingdom), R. Free (Leicester, United Kingdom)
| |
The efficacy of telavancin in comparison to linezolid on endotracheal tube biofilm in pigs with MRSA pneumonia> K. KIAROSTAMI (Barcelona, Spain), D. Battaglini (Genoa, Italy), A. Motos (Barcelona, Spain), L. Bueno Freire (Barcelona, Spain), A. Soler Comas (Barcelona, Spain), H. Yang (Barcelona, Spain), M. Yang (Barcelona, Spain), F. Pagliara (Genoa, Italy), E. Aguilera Xiol (Barcelona, Spain), A. Meli (Barcelona, Spain), J. Bobi (Barcelona, Spain), T. Senussi Testa (Genoa, Italy), F. Idone (Rome, Italy), M. Rigol (Barcelona, Spain), G. Li Bassi (Barcelona, Spain), L. Fernández-Barat (Barcelona, Spain), A. Torres (Barcelona, Spain)
| |
Clinical efficacy between cefoperazone-sulbactam and prolonged infusion of piperacillin-tazobactam in the treatment of severe CAP, HAP and VAP: a retrospective multicenter cohort study C. Sun (Taipei, Taiwan), W. Chen (Taipei, Taiwan)
| |
Investigating neutrophil AMPK activity in COVID-19 and pneumonia Y. Giam (Dundee (Angus), United Kingdom), M. Long (Dundee (Angus), United Kingdom), L. Delgado (Dundee (Angus), United Kingdom), H. Abo-Leyah (Dundee (Angus), United Kingdom), H. Keir (Dundee (Angus), United Kingdom), T. Pembridge (Dundee (Angus), United Kingdom), R. Hull (Sheffield, United Kingdom), A. Gilmour (Dundee (Angus), United Kingdom), C. Hughes (Dundee (Angus), United Kingdom), H. Richardson (Dundee (Angus), United Kingdom), D. Cassidy (Dundee (Angus), United Kingdom), A. Shoemark (Dundee (Angus), United Kingdom), J. Chalmers (Dundee (Angus), United Kingdom)
| |
Monitoring COVID-19 pneumonia undergoing non-invasive respiratory support (NIRS), correlation between oscillometric reactance and Thoracic CT C. Torregiani (Trieste, Italy), C. Veneroni (Milano, Italy), E. Baratella (Trieste, Italy), A. Segalotti (Trieste, Italy), S. Tavano (Trieste, Italy), G. Lapadula (Trieste, Italy), C. Bozzi (Trieste, Italy), B. Ruaro (Trieste, Italy), M. Confalonieri (Trieste, Italy), R. Dellacà (Milano, Italy)
| |
Lung ultrasound score for pediatric pneumonia surveillance I. Ciuca (Timisoara (Timis), Romania), M. Marc (Timisoara, Romania), M. Dediu (Timisoara, Romania), D. Popin (Timisoara, Romania), P. Liviu (Timisoara, Romania)
| |
Phase 3 RCT of C5a-Specific Vilobelimab in Severe COVID-19 Pneumonia A. Vlaar (Amsterdam, Netherlands), G. Hermans (Leuven, Belgium), M. Witzenrath (Berlin, Germany), P. Van Paassen (Maastricht, Netherlands), L. Heunks (Amsterdam, Netherlands), B. Mourvillier (Reims, France), S. De Bruin (Amsterdam, Netherlands), E. Lim (Amsterdam, Netherlands), M. Piagnerelli (Charleroi, Belgium), A. Roquilly (Nantes, France), J. Lascarrou (Nantes, France), M. Bauer (Jena, Germany), C. Schwebel (Grenoble, France), M. Brouwer (Amsterdam, Netherlands), P. Tuinman (Amsterdam, Netherlands), T. Welte (Hannover, Germany), G. Marx (Leuven, Belgium), U. Jaschinski (Augsburg, Germany), A. Cornet (Enschede, Netherlands), A. Grebenyuk (Barnaul, Russian Federation), P. Jorens (Antwerp, Belgium), S. Rückinger (Munich, Germany), K. Pilz (Jena, Germany), C. Thielert (Jena, Germany), D. Neukirchen (Jena, Germany), L. Ruckerbauer (Munich, Germany), B. Burnett (Ann Arbor, United States), R. Guo (Ann Arbor, United States), D. Van De Beek (Amsterdam, Netherlands), N. Riedemann (Jena, Germany)
| |
Therapeutic stategies in hospitalised patients with SarsCov-2 hipoxemic pneumonia P. Cunha (Guimarães, Portugal), C. Castro (Guimarães, Portugal), H. Sarmento (Guimarães, Portugal), I. Vila (Guimarães, Portugal), M. Vieira (Guimarães, Portugal), A. Costa (Guimarães, Portugal), A. Amorim (Guimarães, Portugal), M. Correia-Neves (Guimarães, Portugal), J. Cotter (Guimarães, Portugal)
| |
Late Breaking Abstract - Effect of N-acetyl cysteine in a patient cohort with severe or very severe COVID-19 pneumonia C. Gotera Rivera (Madrid, Spain), C. López Chang (Madrid, Spain), L. De La Dueña (Madrid, Spain), L. Llanos Jiménez (Madrid, Spain), R. Cortés (Madrid, Spain), O. Sánchez Pernaute (Madrid, Spain), C. Pérez Calvo (Madrid, Spain), A. Ioan (Madrid, Spain), J. Pérez (Madrid, Spain), A. Santos Oviedo (Madrid, Spain), S. Heili Frades (Madrid, Spain), A. Naya Prieto (Madrid, Spain), I. Fernández Ormaechea (Madrid, Spain), M. Carballosa De Miguel (Madrid, Spain), M. Rodríguez Nieto (Madrid, Spain), G. Peces Barba (Madrid, Spain)
| |
Accuracy of rapid diagnostics for community-acquired pneumonia in the emerging room M. Sanguinetti (Rome, Italy)
| |
Longitudinal chest-CT findings after moderate to critical COVID-19 pneumonia A. Flikweert (Breda, Netherlands), A. Du Mee (Breda, Netherlands), I. De Backer (Breda, Netherlands), S. van der Sar (Breda, Netherlands)
| |
The lung microbiome and pneumonia: is dysbiosis the new pathway to investigate these infections ? L. Segal (New York
New York, NY, United States)
| |
Virtual reality intervention alleviates dyspnea in patients recovering from COVID pneumonia S. Betka (Genève, Switzerland), K. Oliver (Genève, Switzerland), F. Jemina (Genève, Switzerland), L. Florian (Genève, Switzerland), C. Sylvain (Lausanne, Switzerland), S. Aline (Genève, Switzerland), S. Thomas (Paris, France), S. Paola (Genève, Switzerland), H. Bruno (Genève, Switzerland), A. Dan (Genève, Switzerland), B. Olaf (Genève, Switzerland)
| |
Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients D. Price (Singapore, Singapore), W. Henley (Singapore, Singapore), V. Carter (Singapore, Singapore), D. Skinner (Singapore, Singapore), R. Vella (Singapore, Singapore), A. Papi (Ferrara, Italy), L. Fabbri (Ferrara, Italy), H. Kerstjens (Groningen, Germany), N. Roche (Paris, France), D. Singh (Manchester, United Kingdom), C. Vogelmeier (Marburg, Germany), E. Sen (Ankara, Turkey), J. Cançado (São Paulo, Brazil), M. Kots (Parma, Italy), E. Nudo (Parma, Italy), S. Barile (Parma, Italy), G. Georges (Parma, Italy), W. Henley (United Kingdom)
| |
Surfactant protein-A (SP-A) is a novel marker of lung disorders in patients discharged after COVID-19 pneumonia O. Shchudro (Dnipro, Ukraine), L. Konopkina (Dnipro, Ukraine)
| |
Gas exchange after Covid-19 pneumonia S. Mokaddem Mohsen (Ariana, Tunisia), K. Kechaou (Ariana, Tunisia), M. Maalej (Ariana, Tunisia), A. Chaker (Ariana, Tunisia), N. Ben Lazreg (Ariana, Tunisia), S. Ben Khamsa Jameleddine (Ariana, Tunisia)
| |
Imaging of complicated pneumonia: what is new? A. Bush (London, United Kingdom), J. Lovrenski (Novi Sad, Serbia), E. Alexopoulou (Athens, Greece), S. Unger (Edinburgh, United Kingdom)
Monday, 7 November 2022 | |
Bilateral interstitial pneumonia in an 8-year-old boy: not only COVID-19! M. Di Cicco (Pisa (PI), Italy)
| |
Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD) D. Dos Reis Estrella ( Belo Horizonte (MG), Brazil), F. Sacilotto Donaires (Ribeirão Preto (SP), Brazil), A. Pinto Santos (Ribeirão Preto (SP), Brazil), E. Viana Mancuzo (Belo Horizonte (MG), Brazil), R. Tocantins Calado (Ribeirão Preto (SP), Brazil), R. De Amorim Corrêa (Belo Horizonte (MG), Brazil)
| |
Bronchoalveolar lavage fluid (BALF) findings in patients with immune checkpoint inhibitor (ICI)-associated interstitial pneumonia (IP) L. Jehn (Essen, Germany), J. Wälscher (Essen, Germany), T. Wessendorf (Essen, Germany), E. Livingstone (Essen, Germany), L. Zimmer (Essen, Germany), M. Metzenmacher (Essen, Germany), W. Eberhardt (Essen, Germany), D. Theegarten (Essen, Germany), F. Bonella (Essen, Germany)
| |
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation C. Seebacher (Bolzano (BZ), Italy), G. Resch (Bolzano (BZ), Italy), E. Stirpe (Bolzano (BZ), Italy), R. Dongilli (Bolzano (BZ), Italy), L. Bonazza (Bolzano (BZ), Italy), P. Pernter (Bolzano (BZ), Italy), F. Ferro (Bolzano (BZ), Italy)
| |
Consequences of SARS-COV-2 Pneumonia on Lung function N. Orzes (Brescia, Italy), L. Pini (Brescia, Italy), G. Levi (Brescia, Italy), S. Uccelli (Brescia, Italy), F. Cettolo (Brescia, Italy), J. Giordani (Brescia, Italy), A. Pini (Paris, France), M. Guerini (Brescia, Italy), M. Ciarfaglia (Brescia, Italy), C. Tantucci (Brescia, Italy)
| |
Discussion and Q&A
| |
Antimicrobial resistance and new therapeutic options K. Crothers (Seattle, United States of America)
| |
Advances in diagnostic tools for lower respiratory tract infections C. Prat Aymerich (Badalona (Barcelona), Spain)
| |
The challenges of viral pneumonia in the post-COVID era C. García-Vidal (Barcelona, Spain)
| |
Rethinking the guidelines after COVID-19 I. Martin-Loeches (Dublin, Ireland)
| |
Late Breaking Abstract - Lung function tests in patients with previous SARS-COV2 pneumonia: a useful follow-up tool L. Pini (Brescia, Italy), R. Montori (Brescia, Italy), J. Giordani (Brescia, Italy), A. Pini (Paris, France), M. Guerini (Brescia, Italy), N. Orzes (Brescia, Italy), M. Ciarfaglia (Brescia, Italy), C. Tantucci (Brescia, Italy)
| |
Chronic cough associated with COPD exacerbation, pneumonia and death: A prospective study of the general population E. Landt (Køge, Denmark), Y. Çolak (Herlev, Denmark), B. Nordestgaard (Herlev, Denmark), P. Lange (Herlev, Denmark), M. Dahl (Køge, Denmark)
| |
Association between symptoms and objective physiological outcomes in severe COVID-19 pneumonia survivors P. Zamani (London, United Kingdom), S. Mehrotra (London, United Kingdom), R. D'Cruz (London, United Kingdom), S. Mathew (London, United Kingdom), A. Byrne (London, United Kingdom), M. Choudhury (London, United Kingdom), T. Fleming (London, United Kingdom), S. Norton (London, United Kingdom), S. Birring (London, United Kingdom), A. Patel (London, United Kingdom), I. Patel (London, United Kingdom), F. Perrin (London, United Kingdom), M. Waller (London, United Kingdom), C. Jolley (London, United Kingdom)
| |
ROX index validity for predicting mechanical ventilation requirement in pneumonia A. Bastidas (Chía, Colombia), K. Pedreros (Chía, Colombia), M. Herrera (Chía, Colombia), G. Carmona (Chía, Colombia), L. Saza (Chía, Colombia), L. Bello (Chía, Colombia), C. Muñoz (Chía, Colombia), J. Chavez (Chía, Colombia), J. Arias (Chía, Colombia), P. Alcaraz (Chía, Colombia), M. Hernandez (Chía, Colombia), A. Nonzoque (Chía, Colombia), N. Trujillo (Chía, Colombia), A. Pineda (Chía, Colombia), G. Montaño (Chía, Colombia), L. Reyes (Chía, Colombia), M. Herrera Tamayo (Bogotá, Colombia)
| |
Management of community-acquired pneumonia: new evidence-based algorithms. E. Tacconelli (Italy)
| |
Potential impact and relevance of diagnostics in the management of respiratory tract infections: from COVID to hospital-acquired pneumonia M. Sanguinetti (Rome, Italy)
| |
Tofacitinib versus standard of care treatment in patients with COVID-19 pneumonia and respiratory failure: a multicenter cohort study L. Akulkina (Moscow, Russian Federation), M. Brovko (Moscow, Russian Federation), N. Bulanov (Moscow, Russian Federation), P. Novikov (Moscow, Russian Federation), A. Zykova (Moscow, Russian Federation), V. Sholomova (Moscow, Russian Federation), A. Moiseev (Moscow, Russian Federation), A. Schepalina (Moscow, Russian Federation), A. Kitbalian (Moscow, Russian Federation), N. Chichkova (Moscow, Russian Federation), V. Fomin (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), N. Trushenko (Moscow, Russian Federation), S. Moiseev (Moscow, Russian Federation)
| |
Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone D. Price (Singapore, Singapore), W. Henley (Singapore, Singapore), V. Carter (Singapore, Singapore), D. Skinner (Singapore, Singapore), R. Vella (Singapore, Singapore), A. Papi (Ferrara, Italy), L. Fabbri (Ferrara, Italy), H. Kerstjens (Groningen, Netherlands), N. Roche (Paris, France), D. Singh (Manchester, United Kingdom), C. Vogelmeier (Marburg, Germany), E. Sen (Ankara, Turkey), J. Cançado (São Paulo, Brazil), E. Nudo (Parma, Italy), S. Barile (Parma, Italy), G. Georges (Parma, Italy)
| |
Corticosteroids in severe pneumonia. A propensity score matching study based on real-life. A. Ceccato (barcelona, Spain), A. Russo (Pisa, Italy), E. Barbeta (Barcelona, Spain), P. Oscanoa (Barcelona, Spain), G. Tiseo (Pisa, Italy), A. Gabarrus (Barcelona, Spain), P. Di Giannatale (Pescara, Italy), S. Nogas (Genoa, Italy), F. Menichetti (Pisa, Italy), M. Ferrer (Barcelona, Spain), M. Falcone (Pisa, Italy), A. Torres (Barcelona, Spain)
| |